Zyvirab D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, promoting mucosal healing and symptom relief. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance through reduced dosing frequency. Zyvirab D Capsule SR is indicated for patients experiencing acid reflux, heartburn, and delayed gastric emptying, providing symptomatic relief and improving quality of life. It is contraindicated in individuals with known hypersensitivity to either component and should be used cautiously in patients with liver impairment or underlying cardiac conditions. The combination therapy offers a synergistic approach by addressing both acid suppression and motility enhancement, making it a valuable option in the comprehensive management of upper gastrointestinal motility and acid-related disorders. Patients should adhere to prescribed dosages and consult healthcare professionals for any adverse reactions.